TD 001
Alternative Names: TD-001Latest Information Update: 27 Jun 2025
At a glance
- Originator T.O.A.D. Oncology SA
- Class Alkaloids; Antineoplastics; Camptothecins; Drug conjugates; Immunoconjugates; Monoclonal antibodies
- Mechanism of Action DNA topoisomerase I inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Prostate cancer
Most Recent Events
- 25 Apr 2025 Preclinical trials in Prostate cancer in Switzerland (IV) prior to April 2025
- 25 Apr 2025 Pharmacodynamics and pharmacokinetics data from a preclinical study in Prostate cancer presented at the 116th Annual Meeting of the American Association for Cancer Research (AACR-2025)
- 25 Apr 2025 Pharmacodynamics data from a preclinical study in Prostate cancer presented at the 116th Annual Meeting of the American Association for Cancer Research (AACR-2025)